Rawpixel.com / Shutterstock.com
7 April 2016AmericasDarryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang
Amgen v Sandoz: marketing exclusivity under the BPCIA
On February 16, 2016, Sandoz filed a petition for a writ of certiorari asking the US Supreme Court to review the case Amgen v Sandoz, in which the US Court of Appeals for the Federal Circuit interpreted key provisions of the Biologics Price Competition and Innovation Act (BPCIA) (codified at 42 USC §262[k]).
